Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Eur J Pediatr ; 182(4): 1897-1909, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-36801975

RESUMO

Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe disease temporarily related to SARS-CoV-2. We aimed to describe the epidemiological, clinical, and laboratory findings of all MIS-C cases diagnosed in children < 18 years old in Catalonia (Spain) to study their trend throughout the pandemic. This was a multicenter ambispective observational cohort study (April 2020-April 2022). Data were obtained from the COVID-19 Catalan surveillance system and from all hospitals in Catalonia. We analyzed MIS-C cases regarding SARS-CoV-2 variants for demographics, symptoms, severity, monthly MIS-C incidence, ratio between MIS-C and accumulated COVID-19 cases, and associated rate ratios (RR). Among 555,848 SARS-CoV-2 infections, 152 children were diagnosed with MIS-C. The monthly MIS-C incidence was 4.1 (95% CI: 3.4-4.8) per 1,000,000 people, and 273 (95% CI: 230-316) per 1,000,000 SARS-CoV-2 infections (i.e., one case per 3,700 SARS-CoV-2 infections). During the Omicron period, the MIS-C RR was 8.2 (95% CI: 5.7-11.7) per 1,000,000 SARS-CoV-2 infections, which was significantly lower (p < 0.001) than that for previous variant periods in all age groups. The median [IQR] age of MIS-C was 8 [4-11] years, 62.5% male, and 80.2% without comorbidities. Common symptoms were gastrointestinal findings (88.2%) and fever > 39 °C (81.6%); nearly 40% had an abnormal echocardiography, and 7% had coronary aneurysm. Clinical manifestations and laboratory data were not different throughout the variant periods (p > 0.05).  Conclusion: The RR between MIS-C cases and SARS-CoV-2 infections was significantly lower in the Omicron period for all age groups, including those not vaccinated, suggesting that the variant could be the main factor for this shift in the MISC trend. Regardless of variant type, the patients had similar phenotypes and severity throughout the pandemic. What is Known: • Before our study, only two publications investigated the incidence of MIS-C regarding SARS-CoV-2 variants in Europe, one from Southeast England and another from Denmark. What is New: • To our knowledge, this is the first study investigating MIS-C incidence in Southern Europe, with the ability to recruit all MIS-C cases in a determined area and analyze the rate ratio for MIS-C among SARS-CoV-2 infections throughout variant periods. • We found a lower rate ratio of MISC/infections with SARS-CoV-2 in the Omicron period for all age groups, including those not eligible for vaccination, suggesting that the variant could be the main factor for this shift in the MISC trend.


Assuntos
COVID-19 , SARS-CoV-2 , Masculino , Humanos , Feminino , COVID-19/diagnóstico , COVID-19/epidemiologia , Espanha/epidemiologia , Estudos de Coortes
3.
Children (Basel) ; 9(8)2022 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-36010050

RESUMO

BACKGROUND: Breastfeeding prevents Kawasaki disease (KD), as well as several autoimmune disorders. Since there is an overlap between the Multi-System Inflammatory Syndrome in children following SARS-CoV-2 infection (MIS-C) and KD, this case series aims to analyze the association between breastfeeding and MIS-C. METHODS: A series of 16 cases of children with MIS-C admitted to three pediatric facilities between January 2021 and May 2022 were conducted. Breastfeeding rate was estimated through the Brief Breastfeeding and Milk Expression Recall Survey. RESULTS: Out of 16 children, 9 (56%) had been breastfed at birth. DISCUSSION: Our breastfeeding rate is below the median Spanish rate for initial breastfeeding. These findings do not clearly support the hypothesis that breastfeeding might prevent MIS-C. CONCLUSION: Contrary to the role of breastfeeding in KD prevention, our case series cannot answer with certainty the question about whether or not breastfeeding does protect children against MIS-C. These findings require confirmation in larger studies.

4.
J Child Neurol ; 37(2): 141-150, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35001699

RESUMO

Neurologic complications following stem cell transplantation are of utmost importance owing to their high morbimortality. Although many studies have been performed in the adult population, reports in children are scarce. Our objective was to determine the most common neurologic complications in a pediatric population and to analyze possible risk factors for their development. We performed an exploratory retrospective study of neurologic complications in pediatric patients who had allogeneic stem cell transplantation over the last 18 years. We identified 66 neurologic complications in 178 allogeneic stem cell transplantations. The most frequent neurologic complications were those involving the peripheral nervous system and those related to drug toxicity. Survival decreased significantly in the presence of neurologic complications. Multivariate logistic regression analysis showed that independent risk factors for developing neurologic complications were development of chronic extensive graft-vs-host disease requiring treatment, cytomegalovirus reactivation, and central nervous system radiation. Prompt diagnosis and preemptive treatment, if possible, are necessary to avoid long-term sequelae or mortality.


Assuntos
Doenças do Sistema Nervoso/etiologia , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Células-Tronco , Transplante Homólogo/efeitos adversos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Avaliação de Resultados em Cuidados de Saúde/métodos , Estudos Retrospectivos , Fatores de Risco , Transplante Homólogo/estatística & dados numéricos
7.
J Antimicrob Chemother ; 51(1): 163-6, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12493803

RESUMO

This study further evaluated the in vitro activity of anidulafungin (VER002, Versicor Inc.) (LY303366) against 460 clinical yeast isolates. MICs of anidulafungin, fluconazole and itraconazole were determined by following the NCCLS M27-A guidelines. Minimum fungicidal concentrations (MFCs) of anidulafungin were determined for 230 isolates of Candida spp. The activity of anidulafungin in vitro was significantly superior (P < 0.05) to those of itraconazole and fluconazole against Candida albicans, Candida tropicalis, Candida glabrata and Candida krusei, but anidulafungin was less active for Candida famata and Candida parapsilosis. The differences were not significant for the other species evaluated.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Peptídeos Cíclicos/farmacologia , Anidulafungina , Candida/isolamento & purificação , Candida/fisiologia , Equinocandinas , Humanos , Testes de Sensibilidade Microbiana/métodos , Testes de Sensibilidade Microbiana/estatística & dados numéricos
8.
Chemotherapy ; 48(5): 224-31, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12476038

RESUMO

We compared the in vitro antifungal activity of amphotericin B lipid complex (ABLC) with that of itraconazole (ITZ) against 535 yeast strains and 173 opportunistic filamentous fungi by using a microdilution method (National Committee for Clinical Laboratory Standards M27-A and M38-P). The overall geometric mean MIC was 0.13 microg/ml and 0.177 microg/ml for ITZ and ABLC, respectively, and the MIC(50) was 0.125 microg/ml for both agents against yeast isolates. ITZ had a similar or slightly superior efficacy compared to ABLC when tested against Candida albicans, Candida parapsilosis, Cryptococcus neoformans, Candida krusei, Candida glabrata and Candida tropicalis. Effectiveness against C. glabrata was lower for ITZ (MIC(90) 2 microg/ml, and for ABLC, 0.5 microg/ml). For Aspergillus fumigatus, activity of ITZ was superior in comparison with ABLC (MIC(90) 1 and 16 microg/ml, respectively); MIC(90) for Aspergillus niger was 4 and 2 microg/ml for ABLC and ITZ, respectively. Scedosporium spp. showed a low susceptibility to both ABLC and ITZ. In conclusion, ABLC and ITZ are useful alternatives for the treatment of severe fungal infections. The selection of an antifungal agent should be made considering the toxicological and pharmacological properties and cost/benefit relationship and be supported by the susceptibility of the isolate.


Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Fungos/efeitos dos fármacos , Itraconazol/farmacologia , Infecções Oportunistas/microbiologia , Fosfatidilcolinas/farmacologia , Fosfatidilgliceróis/farmacologia , Meios de Cultura , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Farmacorresistência Fúngica , Fungos/isolamento & purificação , Humanos , Testes de Sensibilidade Microbiana/métodos , Testes de Sensibilidade Microbiana/normas , Controle de Qualidade , Leveduras/efeitos dos fármacos , Leveduras/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA